注射用头孢哌酮钠舒巴坦钠仿制药与原研药治疗下呼吸道感染的有效性与安全性比较

打开文本图片集

中图分类号：R917文献标识码：A

DOI：10.3969/j.issn.1006-1959.2026.04.027 文章编号：1006-1959（2026）04-0149-04

Abstract：ObjectiveTomparethEfcacyandSafetyofgenericugdriginatordrugofcfoperaoesodndsubactamsod） forinjectioninthetreatentoflowerrespiratorytractifetion（LRTMetodsedataofRpatintsreceivedCSSStreantfro JauaryO4taiosofuzaeople'sspialeerosielyledatitsi Thegenericdugthatsetastegenecuggopandatientseereaedwitteoiginatordrugthatsetasteoriginatorduggrouper screningdopsitoaschstivesroteo indexes，rgeidotalsdsulse the effectiverate of treatment （79.59%vs.83.67 % ），theimprovementrateofinflammatoryindexes （67.35% vs. 75.51% ）and theincidence of adverse reactions （8.16% vs. 6.12 % ） between the generic drug group and the originator drug group （ P> 0.05）.There were no significant diference between the twogroupsintipyetictime，aledisappearancetime，chestX-ayimproementtie，hospitalizationdaysandtotaldugost（ P>0.05 .Conclusion Bothgenericugdgaogofafilialcaoereisintfeide two drugs，and the recovery speed is similar.

Keywords：Lowespiatorytractifection;Cefopazonesodndubctamsodfoection;GenericugOrigiatog;aety

头孢哌酮钠舒巴坦钠（cefoperazone sodium andsulbactamsodium，CSSS）为临床常用抗生素复方制剂，由头孢哌酮（第三代头孢菌素）与舒巴坦（β-内酰胺酶抑制剂）组成，具有抗菌谱广、组织分布好、耐药率低等特点，现广泛应用于下呼吸道感染（lowerrespiratorytractinfection，LRTI）等疾病的临床治疗中[2]。（剩余5513字）